סיפרול 1 מג ישראל - עברית - Ministry of Health

סיפרול 1 מג

boehringer ingelheim israel ltd. - pramipexole dihydrochloride monohydrate - טבליה - pramipexole dihydrochloride monohydrate 1 mg - pramipexole - pramipexole - treatment of signs and symptoms of idiopathic parkinson's disease, as monotherapy or in combination with lovodopa.

סיפרול 0.25 מג ישראל - עברית - Ministry of Health

סיפרול 0.25 מג

boehringer ingelheim israel ltd. - pramipexole dihydrochloride monohydrate - טבליה - pramipexole dihydrochloride monohydrate 0.25 mg - pramipexole - pramipexole - treatment of signs and symptoms of idiopathic parkinson's disease, as monotherapy or in combination with lovodopa. for symptomatic treatment of moderate to severe idiopathic restless legs syndrome.

סיפרול ER 0.375 ישראל - עברית - Ministry of Health

סיפרול er 0.375

boehringer ingelheim israel ltd. - pramipexole dihydrochloride monohydrate - טבליות עם שחרור נרחב - pramipexole dihydrochloride monohydrate 0.375 mg - pramipexole - pramipexole - treatment of signs and symptoms of idiopathic parkinson's disease, as monotherapy or in combination with levodopa.

סיפרול 0.75 ER ישראל - עברית - Ministry of Health

סיפרול 0.75 er

boehringer ingelheim israel ltd. - pramipexole dihydrochloride monohydrate - טבליות עם שחרור נרחב - pramipexole dihydrochloride monohydrate 0.75 mg - pramipexole - pramipexole - treatment of signs and symptoms of idiopathic parkinson's disease, as monotherapy or in combination with levodopa.

סיפרול 1.5 ER ישראל - עברית - Ministry of Health

סיפרול 1.5 er

boehringer ingelheim israel ltd. - pramipexole dihydrochloride monohydrate - טבליות עם שחרור נרחב - pramipexole dihydrochloride monohydrate 1.5 mg - pramipexole - pramipexole - treatment of signs and symptoms of idiopathic parkinson's disease, as monotherapy or in combination with levodopa.

פראמין טבליות ישראל - עברית - Ministry of Health

פראמין טבליות

rafa laboratories ltd - metoclopramide hydrochloride - טבליה - metoclopramide hydrochloride 10 mg - metoclopramide - metoclopramide - antiemetic and gi motility stimulation. in adult: symptomatic treatment of gi reflux oesophagitis which did not respond to conventional treatment

פראמין זריקות ישראל - עברית - Ministry of Health

פראמין זריקות

rafa laboratories ltd - metoclopramide hydrochloride - תמיסה להזרקה - metoclopramide hydrochloride 5 mg/ml - metoclopramide - metoclopramide - antiemetic and gi motility stimulation. in adults:treatment of sympatomatic gi reflux oesophagitis which did not respond to conventional therapy

סיפרול ER 4.5 מג ישראל - עברית - Ministry of Health

סיפרול er 4.5 מג

boehringer ingelheim israel ltd. - pramipexole dihydrochloride monohydrate - טבליות עם שחרור נרחב - pramipexole dihydrochloride monohydrate 4.5 mg - pramipexole - pramipexole - treatment of signs and symptoms of idiopathic parkinson’s disease, as monotherapy or in combination with lovodopa.

אנאפרניל ס.ר.75 מג טבליות ישראל - עברית - Ministry of Health

אנאפרניל ס.ר.75 מג טבליות

tzamal bio-pharma ltd - clomipramine hydrochloride - טבליות בשחרור איטי - clomipramine hydrochloride 75 mg - clomipramine - clomipramine - depression of varying origin: in children and adolescents there is not sufficient evidence of safety and efficacy of anafranil in the treatment of depressive states of varying aetiology and symptomatology. the use of anafranil in children and odolescents ( 0 - 17 years of age ) in this indication is therefore not recommended. obsessive compulcive syndromes: no experience is available in children younger than 5 years of age.

אנאפרניל 25 מג ישראל - עברית - Ministry of Health

אנאפרניל 25 מג

tzamal bio-pharma ltd - clomipramine hydrochloride - טבליות מצופות - clomipramine hydrochloride 25 mg - clomipramine - clomipramine - depression of varying origin: in children and adolescents there is not sufficient evidence of safety and efficacy of anafranil in the treatment of depressive states of varying aetiology and symptomatology. the use of anafranil in children and odolescents ( 0 - 17 years of age ) in this indication is therefore not recommended. obsessive compulcive syndromes: no experience is available in children younger than 5 years of age.